Ocrelizumab Trial Fills Research Gap for Black, Hispanic MS Patients

Half of patients had no evidence of disease activity at 48 weeks

Related Keywords

Texas ,United States ,Kenya ,Nairobi ,Nairobi Area ,America ,American ,Sophie Putka ,Los Angeles ,Lilyana Amezcua ,American Academy Of Neurology ,University Of Texas At Austin ,Ms Minority Research Network ,University Of Southern California ,Sclerosis Association Of America ,African American ,American Academy ,Southern California ,Research Network ,Multiple Sclerosis Association ,Expanded Disability Status Scale ,Wall Street Journal ,Business Insider ,Cannabis Wire ,Medpage Today ,